That's a useless abstract. It says nothing about what the intervention actually is, nor about what changed.
Inclusion criteria were that children: (a) were between 10 and 17 years old, (b) had one or more FSS including headache, gastrointestinal symptoms, musculoskeletal pain, chronic fatigue, fibromyalgia, irritable bowel syndrome, symptoms related to chronic Lyme disease, perceived cognitive impairment, or other nonspecific symptoms not attributable to a known biomedical disorder despite adequate evaluation, (c) had symptoms for at least 3 months with some degree of impairment (e.g., missing school), (d) were proficient in English, and (e) lived with their participating parent >50% of the time.
Treatment groups meet once per week for seven consecutive weeks. Each session lasted 1.5 h, scheduled in the evenings (after work hours) to promote accessibility. Only parents, not children, attended the treatment sessions, which were conducted over Zoom. Families received the intervention at no cost.
SPACE-Somatic was adapted from the original SPACE protocol for child anxiety disorders/OCD and informed by FSS theory and research. The protocol is manualized but designed to be implemented flexibly. It includes six parts implemented sequentially over the seven group sessions. Each session involves active discussion and practice of skills in addition to didactic components. Parents are also given tasks to complete between sessions and review the following week. The key components of each part of the treatment are presented in Table 1.



Headache, fatigue and muscle pain dominated, with GI disturbance, abdominal pain, POTS, dizziness/vertigo also highly represented.
Note the drop-out rate: 17 families contacted researchers; 16 did treatment; 13 at 1 week post-intervention follow-up; 11 at 12 weeks follow-up, with 2 lost to follow-up. At early follow-up, 1 discontinued treatment because "child's symptoms improved", 2 "scheduling conflicts".
We also found preliminary evidence that SPACE-Somatic may be beneficial for improving symptoms and functioning in children with FSS. There was a statistically significant change in parent reports of children’s level of functional disability and health-related quality of life, and in parent and child reports of children’s symptom-related impairment, following treatment. Parent reports also provided evidence of maintenance 3 months later. Findings must be interpreted with caution, as the sample size limited our ability to detect moderate or smaller effects. Yet, it is promising that descriptively, all child- and parent-report measures assessing children’s FSS showed improvements across time points. Future studies containing larger, randomly assigned samples, will provide additional rigorous tests of this initial indication that SPACE-Somatic improves children’s functioning and symptoms.
While it is a strength that we collected both parent- and child-report measures at three time points, there were more missing child-report than parent-report data at 3-month FU. The parent-report data also showed more significant improvements following treatment than did the child-report data, likely impacted by the lower degree of missing data.
It is unclear, for example, whether the higher proportion of missing data and fewer significant child-report findings in our study reflect lower levels of child engagement, a possibility that underscores the importance of parent-based work in this population.
Although preliminary, these findings suggest that SPACE-Somatic holds promise as a novel intervention for pediatric FSS by offering parents specific tools for helping their child.